Astrotech Corporation (ASTC) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While ASTC currently carries a cautious 33/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.50) and Max Pain ($5.51) forces dealer call-delta covering toward $72.29.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Astrotech Corporation (ASTC) slipped -0.28% to $5.25, trading at 5% of its 52-week range ($1.92 – $68.85). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
AVSAM proposal targets intelligent, bidirectional lunar power distribution; Lunar Utilities Corporation seeks to develop commercial power and robotic charging services Illustrative schematic of proposed Lunar Utilities C
The proposed project, Astrotech Vertical Solar Array Maturation (AVSAM), would advance critical elements of the Astrotech Mobile Power System (AMPS) for potential future lunar surface use.The proposal targets maturation
Finance, accounting, investor relations, and communications consolidated under the CFO role Stober succeeds David Yablunosky as CFO and assumes responsibilities previously overseen by Roland Austrup ORLANDO, Fla., Oct. 1
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -41.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ASTC today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ASTC. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Astrotech Corporation (ASTC) ranks #883 by composite RQD confidence (33/100, grade E) and #888 by equity capitalization ($11.1M). Within this direct 5-issuer industry benchmark cohort, ASTC leads on earnings valuation at N/A trailing P/E, while PRPO leads on capital efficiency and profitability with -7.9% ROIC and 44.2% gross margin. RPID currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with ASTC at 33/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ASTC
ACTIVE
Astrotech Corporation | E | 33/100 | — | 47.5% | -35.0% | -0.28% | $11.1M | Benchmark Subject |
| BNGO Bionano Genomics Inc. | D- | 36/100 | — | 46.3% | -35.0% | -0.41% | $16.8M | /bngo-vs-astc → |
| EYPT EyePoint Inc. | D- | 38/100 | — | — | -35.0% | +0.69% | $32.8M | /eypt-vs-astc → |
| PRPO Precipio Inc. | D- | 38/100 | — | 44.2% | -7.9% | +3.59% | $34.6M | /prpo-vs-astc → |
| RPID Rapid Micro Biosystems Inc. (Class A) | D | 47/100 | — | — | -35.0% | -1.37% | $39.6M | /rpid-vs-astc → |
In its most recent audited fiscal period (FY2025, filed 2025-06-30), Astrotech Corporation (ASTC) reported GAAP revenue of $1.0M (-41.2% vs. FY2024 revenue of $1.7M , and +33.3% cumulative change since FY2023) , GAAP net income of -$13.8M, operating cash flow of -$13.0M, and free cash flow of -$13.8M (-33.8% YoY). On the balance sheet, ASTC closed FY2025 with $19.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-06-30 | $1.0M | -$13.8M | -$13.0M | -$13.8M | $19.7M | — |
| FY2024 (FY) | 2024-06-30 | $1.7M | -$11.7M | -$9.7M | -$10.3M | $31.0M | — |
| FY2023 (FY) | 2023-06-30 | $750.0K | -$9.6M | -$7.6M | -$7.6M | — | — |
As of 2026-11-01, Astrotech Corporation (NASDAQ: ASTC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $5.25 (-0.28% 1D, market cap $11.1M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ASTC ranks #883 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), ASTC carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of 47.5%, and ROIC of -35.0%. By comparison, BNGO (Bionano Genomics Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $16.8M) and EYPT (EyePoint Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $32.8M). Among the 5-stock peer group, ASTC leads on earnings multiple (N/A) while PRPO leads on capital efficiency (-7.9% ROIC).
Per ASTC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001001907), Astrotech Corporation generated $1.0M in revenue (-41.2% YoY), -$13.8M in net income, and -$13.8M in free cash flow against $19.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ASTC last traded at $5.25 (-0.28% on volume of 13,924 shares), positioning the stock -19.23% below its 50-day simple moving average ($6.50) and -27.18% below its 200-day simple moving average ($7.21). Across its 52-week range of $1.92 to $68.85, ASTC sits at the 5.0% percentile with a 14-day RSI of 30.6 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($4.59 to $5.91).
Why ASTC Stock slipped -0.28% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.